BRPI0821209A2 - composto, composição farmacêutica, métodos de tratar câncer, para reduzir o tamanho de tumor, para tratar distúrbios, e para reduzir metástase em um tumor. - Google Patents
composto, composição farmacêutica, métodos de tratar câncer, para reduzir o tamanho de tumor, para tratar distúrbios, e para reduzir metástase em um tumor.Info
- Publication number
- BRPI0821209A2 BRPI0821209A2 BRPI0821209A BRPI0821209A BRPI0821209A2 BR PI0821209 A2 BRPI0821209 A2 BR PI0821209A2 BR PI0821209 A BRPI0821209 A BR PI0821209A BR PI0821209 A BRPI0821209 A BR PI0821209A BR PI0821209 A2 BRPI0821209 A2 BR PI0821209A2
- Authority
- BR
- Brazil
- Prior art keywords
- reducing
- tumor
- compound
- methods
- pharmaceutical composition
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 3
- 206010027476 Metastases Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000009401 metastasis Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US842907P | 2007-12-19 | 2007-12-19 | |
PCT/US2008/013849 WO2009085185A1 (en) | 2007-12-19 | 2008-12-18 | Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0821209A2 true BRPI0821209A2 (pt) | 2019-09-24 |
Family
ID=40551520
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0821209A BRPI0821209A2 (pt) | 2007-12-19 | 2008-12-18 | composto, composição farmacêutica, métodos de tratar câncer, para reduzir o tamanho de tumor, para tratar distúrbios, e para reduzir metástase em um tumor. |
Country Status (18)
Country | Link |
---|---|
US (2) | US8841312B2 (pt) |
EP (1) | EP2231656A1 (pt) |
JP (1) | JP5537439B2 (pt) |
KR (1) | KR20100095020A (pt) |
CN (1) | CN101945867A (pt) |
AU (1) | AU2008343932B2 (pt) |
BR (1) | BRPI0821209A2 (pt) |
CA (1) | CA2709202C (pt) |
CO (1) | CO6290648A2 (pt) |
CR (1) | CR11573A (pt) |
EA (1) | EA201001030A1 (pt) |
IL (1) | IL206070A0 (pt) |
MA (1) | MA32014B1 (pt) |
MX (1) | MX2010006457A (pt) |
NZ (1) | NZ586069A (pt) |
TN (1) | TN2010000236A1 (pt) |
WO (1) | WO2009085185A1 (pt) |
ZA (2) | ZA201004668B (pt) |
Families Citing this family (124)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2606783C (en) | 2005-05-10 | 2014-03-25 | Incyte Corporation | Modulators of indoleamine 2,3-dioxygenase and methods of using the same |
WO2009085185A1 (en) * | 2007-12-19 | 2009-07-09 | Amgen Inc. | Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors |
UY31631A1 (es) | 2008-02-06 | 2009-09-30 | Nuevos derivados de 7-fenil-7h-pirrolo-[2,3d]-pirimidin-2-il-amino, sales de los mismos, procesos para su preparacion, composiciones farmacéuticas que los comprenden y aplicaciones | |
WO2009126584A1 (en) * | 2008-04-07 | 2009-10-15 | Amgen Inc. | Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors |
PT2824100T (pt) | 2008-07-08 | 2018-05-10 | Incyte Holdings Corp | 1,2,5-oxadiazoles como inibidores da indoleamina 2,3-dioxigenase |
CA2734486A1 (en) * | 2008-08-20 | 2010-02-25 | Southern Research Institute | Substituted pyridine and pyrimidine derivatives and their use in treating viral infections |
DK2331547T3 (da) * | 2008-08-22 | 2014-11-03 | Novartis Ag | Pyrrolopyrimidinforbindelser som CDK-inhibitorer |
AU2010234241A1 (en) | 2009-04-09 | 2011-09-08 | Boehringer Ingelheim International Gmbh | Inhibitors of HIV replication |
CA2761896A1 (en) | 2009-05-13 | 2010-11-18 | The University Of North Carolina At Chapel Hill | Cyclin dependent kinase inhibitors and methods of use |
UY33227A (es) | 2010-02-19 | 2011-09-30 | Novartis Ag | Compuestos de pirrolopirimidina como inhibidores de la cdk4/6 |
JO2998B1 (ar) | 2010-06-04 | 2016-09-05 | Amgen Inc | مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان |
EP2955183A1 (en) | 2010-10-25 | 2015-12-16 | G1 Therapeutics, Inc. | Cdk inhibitors |
US8691830B2 (en) | 2010-10-25 | 2014-04-08 | G1 Therapeutics, Inc. | CDK inhibitors |
WO2012068381A2 (en) | 2010-11-17 | 2012-05-24 | The University Of North Carolina At Chapel Hill | Protection of renal tissues from schema through inhibition of the proliferative kisses cdk4 and cdk6 |
MY161199A (en) | 2011-03-23 | 2017-04-14 | Amgen Inc | Fused tricyclic dual inhibitors of cdk 4/6 and flt3 |
NO2694640T3 (pt) | 2011-04-15 | 2018-03-17 | ||
WO2013049250A1 (en) | 2011-09-27 | 2013-04-04 | Amgen Inc. | Heterocyclic compounds as mdm2 inhibitors for the treatment of cancer |
EP2831080B1 (en) * | 2012-03-29 | 2017-03-15 | Francis Xavier Tavares | Lactam kinase inhibitors |
UA117347C2 (uk) | 2012-06-13 | 2018-07-25 | Інсайт Холдинґс Корпорейшн | Заміщені трициклічні сполуки як інгібітори fgfr |
WO2014058685A1 (en) * | 2012-10-08 | 2014-04-17 | Merck Sharp & Dohme Corp. | Inhibitors of irak4 activity |
WO2014109858A1 (en) | 2013-01-14 | 2014-07-17 | Amgen Inc. | Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture |
AU2014219075C1 (en) | 2013-02-19 | 2018-09-06 | Amgen Inc. | Cis-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer |
WO2014151863A1 (en) | 2013-03-14 | 2014-09-25 | Amgen Inc. | Heteroaryl acid morpholinone compounds as mdm2 inhibitors for the treatment of cancer |
RS59790B1 (sr) | 2013-03-15 | 2020-02-28 | G1 Therapeutics Inc | Privremena zaštita normalnih ćelija tokom hemoterapije |
CA3152117A1 (en) | 2013-03-15 | 2014-09-18 | G1 Therapeutics, Inc. | Highly active anti-neoplastic and anti-proliferative agents |
CN105263931B (zh) | 2013-04-19 | 2019-01-25 | 因赛特公司 | 作为fgfr抑制剂的双环杂环 |
PT3068393T (pt) | 2013-11-11 | 2022-06-14 | Amgen Inc | Terapia de combinação, incluindo um inibidor de mdm2 e um ou mais agentes farmaceuticamente ativos adicionais para o tratamento de cancros |
US10662193B2 (en) | 2014-01-21 | 2020-05-26 | Ac Immune Sa | Carbazole and carboline compounds for use in the diagnosis, treatment, alleviation or prevention of disorders associated with amyloid or amyloid-like proteins |
US9717735B2 (en) | 2014-04-17 | 2017-08-01 | G1 Therapeutics, Inc. | Tricyclic lactams for use in HSPC-sparing treatments for RB-positive abnormal cellular proliferation |
WO2016040848A1 (en) | 2014-09-12 | 2016-03-17 | G1 Therapeutics, Inc. | Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors |
EP3191098A4 (en) | 2014-09-12 | 2018-04-25 | G1 Therapeutics, Inc. | Combinations and dosing regimes to treat rb-positive tumors |
WO2016067009A1 (en) * | 2014-10-28 | 2016-05-06 | Redx Pharma Plc | Compounds with activity against bacteria and mycobacteria |
UA121669C2 (uk) | 2015-02-20 | 2020-07-10 | Інсайт Корпорейшн | Біциклічні гетероцикли як інгібітори fgfr |
MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
WO2016183071A1 (en) | 2015-05-11 | 2016-11-17 | Incyte Corporation | Hetero-tricyclic compounds and their use for the treatment of cancer |
US9725449B2 (en) * | 2015-05-12 | 2017-08-08 | Bristol-Myers Squibb Company | Tricyclic compounds as anticancer agents |
JP6878316B2 (ja) * | 2015-06-19 | 2021-05-26 | ノバルティス アーゲー | Shp2の活性を阻害するための化合物および組成物 |
WO2017027717A1 (en) | 2015-08-12 | 2017-02-16 | Incyte Corporation | Bicyclic fused pyrimidine compounds as tam inhibitors |
US10053465B2 (en) | 2015-08-26 | 2018-08-21 | Incyte Corporation | Pyrrolopyrimidine derivatives as TAM inhibitors |
CN106749259B (zh) * | 2015-11-19 | 2019-02-01 | 华东师范大学 | 一种环戊基嘧啶并吡咯类化合物的合成方法 |
WO2017161253A1 (en) | 2016-03-18 | 2017-09-21 | Tufts Medical Center | Compositions and methods for treating and preventing metabolic disorders |
KR20230111268A (ko) | 2016-03-28 | 2023-07-25 | 인사이트 코포레이션 | Tam 억제제로서 피롤로트리아진 화합물 |
WO2018086591A1 (zh) * | 2016-11-11 | 2018-05-17 | 上海海雁医药科技有限公司 | 吡啶胺取代的杂三环化合物、其制法与医药上的用途 |
WO2018119208A1 (en) | 2016-12-22 | 2018-06-28 | Global Blood Therapeutics, Inc. | Histone methyltransferase inhibitors |
EA201991622A1 (ru) | 2017-01-06 | 2020-01-23 | Г1 Терапьютикс, Инк. | Комплексная терапия для лечения рака |
CN108314686A (zh) * | 2017-01-18 | 2018-07-24 | 西南民族大学 | 一种新颖的Ribociclib制备方法 |
CN108586356B (zh) * | 2017-03-16 | 2021-02-19 | 杭州科巢生物科技有限公司 | 瑞博西尼新中间体及其制备瑞博西尼的合成方法 |
CN108623599A (zh) * | 2017-03-17 | 2018-10-09 | 西南民族大学 | 一种快速合成Ribociclib方法 |
JOP20190272A1 (ar) | 2017-05-22 | 2019-11-21 | Amgen Inc | مثبطات kras g12c وطرق لاستخدامها |
AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
EP3634962B1 (en) * | 2017-06-09 | 2023-05-24 | Global Blood Therapeutics, Inc. | Azaindole compounds as histone methyltransferase inhibitors |
EA201992768A1 (ru) | 2017-06-29 | 2020-05-19 | Г1 Терапьютикс, Инк. | Морфологические формы g1t38 и способы их получения |
CN109265405B (zh) * | 2017-07-18 | 2021-03-16 | 杭州科巢生物科技有限公司 | 4-氨基-2-氯嘧啶-5-甲醛衍生物及其制备方法 |
CN107383019B (zh) * | 2017-07-28 | 2019-10-15 | 江苏艾凡生物医药有限公司 | 吡唑并[4,3-h]喹唑啉类化合物及其用途 |
EP3988552A1 (en) | 2017-09-27 | 2022-04-27 | Incyte Corporation | Salts of pyrrolotriazine derivatives useful as tam inhibitors |
AU2018388404B2 (en) | 2017-12-22 | 2023-11-02 | HiberCell Inc. | Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors |
WO2019133864A1 (en) | 2017-12-29 | 2019-07-04 | Accutar Biotechnology | DUAL INHIBITORS OF PARP1 and CDK |
SG11202005937QA (en) | 2018-01-08 | 2020-07-29 | G1 Therapeutics Inc | G1t38 superior dosage regimes |
US11491206B1 (en) | 2018-02-13 | 2022-11-08 | Duke University | Compositions and methods for the treatment of trail-resistant cancer |
JP7474709B2 (ja) | 2018-02-27 | 2024-04-25 | インサイト・コーポレイション | A2a/a2b阻害剤としてのイミダゾピリミジン及びトリアゾロピリミジン |
EP3786161A4 (en) * | 2018-04-24 | 2021-05-05 | Shanghai Haiyan Pharmaceutical Technology Co., Ltd | CDK4 / 6 INHIBITOR, PHARMACEUTICALLY ACCEPTABLE SALT, POLYMORPHIC OF THEM AND ASSOCIATED USE |
JP7266043B2 (ja) | 2018-05-04 | 2023-04-27 | アムジエン・インコーポレーテツド | KRas G12C阻害剤及びそれを使用する方法 |
SG11202010636VA (en) | 2018-05-04 | 2020-11-27 | Incyte Corp | Solid forms of an fgfr inhibitor and processes for preparing the same |
MA52493A (fr) | 2018-05-04 | 2021-03-10 | Incyte Corp | Sels d'un inhibiteur de fgfr |
US11168089B2 (en) | 2018-05-18 | 2021-11-09 | Incyte Corporation | Fused pyrimidine derivatives as A2A / A2B inhibitors |
AR117600A1 (es) | 2018-06-29 | 2021-08-18 | Incyte Corp | Formulaciones de un inhibidor de axl / mer |
GEP20237560B (en) | 2018-07-05 | 2023-10-25 | Incyte Corp | Fused pyrazine derivatives as a2a / a2b inhibitors |
KR20210049847A (ko) | 2018-08-24 | 2021-05-06 | 쥐원 쎄라퓨틱스, 인크. | 1,4-디아자스피로[5.5]운데칸-3-온의 개선된 합성 |
US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
JP7377679B2 (ja) | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法 |
US20230065740A1 (en) * | 2018-12-28 | 2023-03-02 | Spv Therapeutics Inc. | Cyclin-dependent kinase inhibitors |
US20220056037A1 (en) * | 2018-12-28 | 2022-02-24 | Spv Therapeutics Inc. | Cyclin-dependent kinase inhibitors |
CN111377921A (zh) * | 2018-12-29 | 2020-07-07 | 武汉光谷通用名药物研究院有限公司 | Cdk4-flt3抑制剂及其用途 |
CN111377922B (zh) * | 2018-12-29 | 2021-12-17 | 武汉光谷通用名药物研究院有限公司 | 稠合三环类化合物及其用途 |
TWI829857B (zh) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶 |
US11384083B2 (en) | 2019-02-15 | 2022-07-12 | Incyte Corporation | Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors |
MA54947A (fr) | 2019-02-15 | 2021-12-22 | Incyte Corp | Biomarqueurs de kinase 2 dépendant de la cycline et leurs utilisations |
TW202100520A (zh) | 2019-03-05 | 2021-01-01 | 美商英塞特公司 | 作為cdk2 抑制劑之吡唑基嘧啶基胺化合物 |
US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
US11919904B2 (en) | 2019-03-29 | 2024-03-05 | Incyte Corporation | Sulfonylamide compounds as CDK2 inhibitors |
US11440914B2 (en) | 2019-05-01 | 2022-09-13 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
US11447494B2 (en) | 2019-05-01 | 2022-09-20 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
EP3738593A1 (en) | 2019-05-14 | 2020-11-18 | Amgen, Inc | Dosing of kras inhibitor for treatment of cancers |
JP7092935B2 (ja) | 2019-05-21 | 2022-06-28 | アムジエン・インコーポレーテツド | 固体形態 |
WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
AR119493A1 (es) * | 2019-07-29 | 2021-12-22 | Servier Lab | Derivados de 3,6-diamino-piridazin-3-ilo, composiciones farmacéuticas que los contienen y sus usos como agentes proapoptóticos |
WO2021022172A1 (en) | 2019-08-01 | 2021-02-04 | Incyte Corporation | A dosing regimen for an ido inhibitor |
JP2023509260A (ja) | 2019-08-14 | 2023-03-08 | インサイト・コーポレイション | Cdk2阻害剤としてのイミダゾリルピリミジニルアミン化合物 |
WO2021072232A1 (en) | 2019-10-11 | 2021-04-15 | Incyte Corporation | Bicyclic amines as cdk2 inhibitors |
PE20221085A1 (es) | 2019-10-14 | 2022-07-05 | Incyte Corp | Heterociclos biciclicos como inhibidores de fgfr |
EP4045047A1 (en) | 2019-10-15 | 2022-08-24 | Amgen Inc. | Combination therapy of kras inhibitor and shp2 inhibitor for treatment of cancers |
WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
CN115151539A (zh) | 2019-12-04 | 2022-10-04 | 因赛特公司 | Fgfr抑制剂的衍生物 |
WO2021113479A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
US20230028414A1 (en) | 2019-12-16 | 2023-01-26 | Amgen Inc. | Dosing regimen of kras g12c inhibitor |
CN116234803A (zh) | 2019-12-23 | 2023-06-06 | 冰洲石生物科技公司 | 用于治疗癌症的雌激素受体降解剂和细胞周期蛋白依赖性激酶抑制剂的组合 |
IL296065A (en) | 2020-03-06 | 2022-10-01 | Incyte Corp | Combined treatment including axl/mer and pd-1/pd-l1 inhibitors |
JP2023522202A (ja) | 2020-04-16 | 2023-05-29 | インサイト・コーポレイション | 融合三環式kras阻害剤 |
US11739102B2 (en) | 2020-05-13 | 2023-08-29 | Incyte Corporation | Fused pyrimidine compounds as KRAS inhibitors |
US10988479B1 (en) | 2020-06-15 | 2021-04-27 | G1 Therapeutics, Inc. | Morphic forms of trilaciclib and methods of manufacture thereof |
WO2022047093A1 (en) | 2020-08-28 | 2022-03-03 | Incyte Corporation | Vinyl imidazole compounds as inhibitors of kras |
WO2022072783A1 (en) | 2020-10-02 | 2022-04-07 | Incyte Corporation | Bicyclic dione compounds as inhibitors of kras |
WO2022155941A1 (en) | 2021-01-25 | 2022-07-28 | Qilu Regor Therapeutics Inc. | Cdk2 inhibitors |
JP2024511295A (ja) * | 2021-03-01 | 2024-03-13 | オリオン・コーポレーション | Cyp11a1阻害薬及びその中間体を調製する方法 |
WO2022206888A1 (en) | 2021-03-31 | 2022-10-06 | Qilu Regor Therapeutics Inc. | Cdk2 inhibitors and use thereof |
JP2024513575A (ja) | 2021-04-12 | 2024-03-26 | インサイト・コーポレイション | Fgfr阻害剤及びネクチン-4標的化剤を含む併用療法 |
WO2022228399A1 (zh) * | 2021-04-27 | 2022-11-03 | 山东轩竹医药科技有限公司 | 三并环类usp1抑制剂及其用途 |
EP4352060A1 (en) | 2021-06-09 | 2024-04-17 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
CA3220274A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
AU2022306671A1 (en) | 2021-07-07 | 2024-01-25 | Incyte Corporation | Tricyclic compounds as inhibitors of kras |
WO2023287896A1 (en) | 2021-07-14 | 2023-01-19 | Incyte Corporation | Tricyclic compounds as inhibitors of kras |
WO2023034290A1 (en) | 2021-08-31 | 2023-03-09 | Incyte Corporation | Naphthyridine compounds as inhibitors of kras |
US20230151005A1 (en) | 2021-09-21 | 2023-05-18 | Incyte Corporation | Hetero-tricyclic compounds as inhibitors of kras |
CA3234375A1 (en) | 2021-10-01 | 2023-04-06 | Incyte Corporation | Pyrazoloquinoline kras inhibitors |
WO2023064857A1 (en) | 2021-10-14 | 2023-04-20 | Incyte Corporation | Quinoline compounds as inhibitors of kras |
TW202320792A (zh) | 2021-11-22 | 2023-06-01 | 美商英塞特公司 | 包含fgfr抑制劑及kras抑制劑之組合療法 |
WO2023102184A1 (en) | 2021-12-03 | 2023-06-08 | Incyte Corporation | Bicyclic amine compounds as cdk12 inhibitors |
US20230183251A1 (en) | 2021-12-10 | 2023-06-15 | Incyte Corporation | Bicyclic amines as cdk12 inhibitors |
WO2023122134A1 (en) | 2021-12-22 | 2023-06-29 | Incyte Corporation | Salts and solid forms of an fgfr inhibitor and processes of preparing thereof |
WO2023116884A1 (en) | 2021-12-24 | 2023-06-29 | Qilu Regor Therapeutics Inc. | Cdk2 inhibitors and use thereof |
WO2023168686A1 (en) | 2022-03-11 | 2023-09-14 | Qilu Regor Therapeutics Inc. | Substituted cyclopentanes as cdk2 inhibitors |
US20230279004A1 (en) | 2022-03-07 | 2023-09-07 | Incyte Corporation | Solid forms, salts, and processes of preparation of a cdk2 inhibitor |
WO2023250430A1 (en) | 2022-06-22 | 2023-12-28 | Incyte Corporation | Bicyclic amine cdk12 inhibitors |
WO2024015731A1 (en) | 2022-07-11 | 2024-01-18 | Incyte Corporation | Fused tricyclic compounds as inhibitors of kras g12v mutants |
Family Cites Families (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1168290A (en) * | 1964-08-27 | 1969-10-22 | Allen & Hanburys Ltd | Novel Heterocyclic Compounds |
IT1153216B (it) | 1981-10-16 | 1987-01-14 | Schering Ag | Procedimento per la preparazione di composti cianoeterociclici |
US6498163B1 (en) | 1997-02-05 | 2002-12-24 | Warner-Lambert Company | Pyrido[2,3-D]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation |
SK12472002A3 (sk) | 2000-03-06 | 2003-04-01 | Warner-Lambert Company | 5-Alkylpyrido[2,3-d]pyrimidínové inhibítory tyrosínových kináz |
AU2001237418B2 (en) | 2000-03-15 | 2007-01-11 | Sanofi-Aventis Deutschland Gmbh | Substituted beta-carbolines with ikb-kinase inhibiting activity |
GB0007371D0 (en) | 2000-03-28 | 2000-05-17 | Astrazeneca Uk Ltd | Chemical compounds |
ATE276257T1 (de) | 2000-06-30 | 2004-10-15 | Banyu Pharma Co Ltd | Pyrazinonderivate |
WO2003062246A1 (en) | 2002-01-22 | 2003-07-31 | Warner-Lambert Company Llc | 2-thia-1,6,8-triaza-naphtalene-2,2-dioxides as cdk inhibitors |
IL162721A0 (en) | 2002-01-22 | 2005-11-20 | Warner Lambert Co | 2-(Pyridin-2-ylamino)-pyridoÄ2,3-dÜpyrimidin-7-ones |
US20030199525A1 (en) | 2002-03-21 | 2003-10-23 | Hirst Gavin C. | Kinase inhibitors |
US7563798B2 (en) | 2002-09-04 | 2009-07-21 | Schering Corporation | Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors |
JP2006516561A (ja) * | 2003-01-17 | 2006-07-06 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | 細胞増殖の阻害剤としての2−アミノピリジン置換ヘテロ環類 |
US7482354B2 (en) * | 2003-05-22 | 2009-01-27 | Nerviano Medical Sciences S.R.L. | Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors |
RU2317296C2 (ru) | 2003-07-11 | 2008-02-20 | Уорнер-Ламберт Компани Ллс | Изетионатная соль селективного ингибитора cdk4 |
WO2005042498A2 (en) | 2003-10-31 | 2005-05-12 | Neurogen Corporation | 4-amino (aza) quinoline derivatives as capsaicin receptor agonists |
GB0329214D0 (en) | 2003-12-17 | 2004-01-21 | Glaxo Group Ltd | Novel compounds |
GB0403606D0 (en) | 2004-02-18 | 2004-03-24 | Novartis Ag | Organic compounds |
JP2007523151A (ja) | 2004-02-18 | 2007-08-16 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | 2−(ピリジン−3−イルアミノ)−ピリド[2,3−d]ピリミジン−7−オン |
BRPI0509580A (pt) | 2004-03-30 | 2007-11-27 | Pfizer Prod Inc | combinações de inibidores de transdução de sinal |
CA2566158A1 (en) | 2004-05-14 | 2005-11-24 | Abbott Laboratories | Kinase inhibitors as therapeutic agents |
EP1781293A1 (en) | 2004-06-04 | 2007-05-09 | Amphora Discovery Corporation | Quinoline- and isoquinoline-based compounds exhibiting atp-utilizing enzyme inhibitory activity, and compositions, and uses thereof |
BRPI0511065A (pt) | 2004-06-04 | 2007-12-26 | Pfizer Prod Inc | método para tratar crescimento de célula anormal |
JP2008510770A (ja) | 2004-08-26 | 2008-04-10 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Plk阻害剤としての新規プテリジノン |
WO2006042102A2 (en) | 2004-10-05 | 2006-04-20 | Neurogen Corporation | Pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds |
CN101035526A (zh) | 2004-10-13 | 2007-09-12 | 默克公司 | 用于治疗高眼压的眼用组合物 |
US20060142312A1 (en) | 2004-12-23 | 2006-06-29 | Pfizer Inc | C6-aryl and heteroaryl substituted pyrido[2,3-D] pyrimidin-7-ones |
US7947695B2 (en) | 2005-01-14 | 2011-05-24 | Janssen Pharmaceutica Nv | 5-membered annelated heterocyclic pyrimidines as kinase inhibitors |
WO2006077428A1 (en) | 2005-01-21 | 2006-07-27 | Astex Therapeutics Limited | Pharmaceutical compounds |
WO2006131552A1 (de) * | 2005-06-09 | 2006-12-14 | Boehringer Ingelheim International Gmbh | Alpha-carboline als cdk-1 inhibitoren |
EP1931683B1 (en) | 2005-08-19 | 2011-07-13 | Schering Corporation | Fused tricyclic mglur1 antagonists as therapeutic agents |
EP1926734A1 (en) | 2005-08-22 | 2008-06-04 | Amgen Inc. | Pyrazolopyridine and pyrazolopyrimidine compounds useful as kinase enzymes modulators |
JP5152922B2 (ja) | 2005-10-06 | 2013-02-27 | メルク・シャープ・アンド・ドーム・コーポレーション | プロテインキナーゼを阻害するためのピラゾロ[1,5−a]ピリミジン誘導体の使用およびプロテインキナーゼを阻害する方法 |
CA2649324A1 (en) | 2006-04-12 | 2007-10-25 | Jean-Damien Charrier | Tetrahydropteridines useful as inhibitors of protein kinases |
WO2007125405A2 (en) | 2006-05-01 | 2007-11-08 | Pfizer Products Inc. | Substituted 2-amino-fused heterocyclic compounds |
JP2009536186A (ja) | 2006-05-08 | 2009-10-08 | アステックス・セラピューティクス・リミテッド | 癌処置のためのジアゾール誘導体の医薬組合せ |
US7893058B2 (en) | 2006-05-15 | 2011-02-22 | Janssen Pharmaceutica Nv | Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases |
US20070270362A1 (en) | 2006-05-18 | 2007-11-22 | The University Of Washington | Methods and compositions for prevention or treatment of inflammatory-related diseases and disorders |
TWI398252B (zh) * | 2006-05-26 | 2013-06-11 | Novartis Ag | 吡咯并嘧啶化合物及其用途 |
EP2035436B1 (en) | 2006-06-26 | 2011-05-25 | UCB Pharma S.A. | Fused thiazole derivatives as kinase inhibitors |
WO2008032157A2 (en) | 2006-09-08 | 2008-03-20 | Pfizer Products Inc. | Synthesis of 2-(pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones |
US20080182853A1 (en) | 2006-12-14 | 2008-07-31 | Inna Kruman | Methods of neuroprotection by cyclin-dependent kinase inhibition |
CA2672960A1 (en) | 2006-12-20 | 2008-07-10 | Schering Corporation | Novel jnk inhibitors |
US20080234262A1 (en) | 2007-03-21 | 2008-09-25 | Wyeth | Pyrazolopyrimidine analogs and their use as mtor kinase and pi3 kinase inhibitors |
WO2009014642A1 (en) | 2007-07-19 | 2009-01-29 | Amgen Inc. | Combination of a de novo purine biosynthesis inhibitor and a cyclin dependent kinase inhibitor for the treatment of cancer |
US7982035B2 (en) | 2007-08-27 | 2011-07-19 | Duquesne University Of The Holy Spirit | Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof |
US7960400B2 (en) | 2007-08-27 | 2011-06-14 | Duquesne University Of The Holy Ghost | Tricyclic compounds having cytostatic and/or cytotoxic activity and methods of use thereof |
US9259399B2 (en) | 2007-11-07 | 2016-02-16 | Cornell University | Targeting CDK4 and CDK6 in cancer therapy |
WO2009061781A1 (en) | 2007-11-07 | 2009-05-14 | Schering Corporation | Novel modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors |
WO2009085185A1 (en) * | 2007-12-19 | 2009-07-09 | Amgen Inc. | Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors |
JP2011509078A (ja) | 2007-12-28 | 2011-03-24 | イプソゲン | 乳癌発現プロファイリング |
AR070127A1 (es) | 2008-01-11 | 2010-03-17 | Novartis Ag | Pirrolo - pirimidinas y pirrolo -piridinas |
MY161199A (en) * | 2011-03-23 | 2017-04-14 | Amgen Inc | Fused tricyclic dual inhibitors of cdk 4/6 and flt3 |
-
2008
- 2008-12-18 WO PCT/US2008/013849 patent/WO2009085185A1/en active Application Filing
- 2008-12-18 AU AU2008343932A patent/AU2008343932B2/en not_active Ceased
- 2008-12-18 KR KR1020107015936A patent/KR20100095020A/ko not_active Application Discontinuation
- 2008-12-18 MX MX2010006457A patent/MX2010006457A/es not_active Application Discontinuation
- 2008-12-18 CN CN2008801270640A patent/CN101945867A/zh active Pending
- 2008-12-18 US US12/808,621 patent/US8841312B2/en active Active
- 2008-12-18 NZ NZ586069A patent/NZ586069A/en not_active IP Right Cessation
- 2008-12-18 JP JP2010539487A patent/JP5537439B2/ja not_active Expired - Fee Related
- 2008-12-18 EA EA201001030A patent/EA201001030A1/ru unknown
- 2008-12-18 BR BRPI0821209A patent/BRPI0821209A2/pt not_active IP Right Cessation
- 2008-12-18 CA CA2709202A patent/CA2709202C/en not_active Expired - Fee Related
- 2008-12-18 EP EP08867586A patent/EP2231656A1/en not_active Withdrawn
-
2010
- 2010-05-27 TN TN2010000236A patent/TN2010000236A1/fr unknown
- 2010-05-30 IL IL206070A patent/IL206070A0/en unknown
- 2010-07-02 ZA ZA2010/04668A patent/ZA201004668B/en unknown
- 2010-07-14 MA MA33013A patent/MA32014B1/fr unknown
- 2010-07-19 CO CO10087751A patent/CO6290648A2/es not_active Application Discontinuation
- 2010-07-19 CR CR11573A patent/CR11573A/es not_active Application Discontinuation
-
2011
- 2011-11-30 ZA ZA2011/08779A patent/ZA201108779B/en unknown
-
2014
- 2014-08-07 US US14/453,842 patent/US8980903B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
EP2231656A1 (en) | 2010-09-29 |
AU2008343932A1 (en) | 2009-07-09 |
EA201001030A1 (ru) | 2011-02-28 |
KR20100095020A (ko) | 2010-08-27 |
CA2709202C (en) | 2013-04-23 |
CA2709202A1 (en) | 2009-07-09 |
IL206070A0 (en) | 2010-11-30 |
JP5537439B2 (ja) | 2014-07-02 |
MA32014B1 (fr) | 2011-01-03 |
ZA201004668B (en) | 2012-03-28 |
US8841312B2 (en) | 2014-09-23 |
ZA201108779B (en) | 2013-02-27 |
US20110142796A1 (en) | 2011-06-16 |
JP2011507849A (ja) | 2011-03-10 |
WO2009085185A1 (en) | 2009-07-09 |
CR11573A (es) | 2010-10-05 |
US20140350244A1 (en) | 2014-11-27 |
CN101945867A (zh) | 2011-01-12 |
AU2008343932B2 (en) | 2013-08-15 |
CO6290648A2 (es) | 2011-06-20 |
TN2010000236A1 (en) | 2011-11-11 |
MX2010006457A (es) | 2010-07-05 |
US8980903B2 (en) | 2015-03-17 |
NZ586069A (en) | 2012-05-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0821209A2 (pt) | composto, composição farmacêutica, métodos de tratar câncer, para reduzir o tamanho de tumor, para tratar distúrbios, e para reduzir metástase em um tumor. | |
BRPI0814542A2 (pt) | Métodos e composições para o tratamento de câncer, tumores e desordens relacionadas a tumores | |
BRPI0811589A2 (pt) | Composição farmacêutica e método para tratar câncer | |
BRPI0818320A2 (pt) | composição para tratamento de câncer de próstata (pca) | |
BRPI0818287A2 (pt) | células dendríticas manipuladas e usos para o tratamento do câncer. | |
BRPI0813311A2 (pt) | Composto, métodos para modulara a atividade de uma proteína quinase e para tratar câncer em um indivíduo, e, composição farmacêutica. | |
BRPI0818426A2 (pt) | produto de combinação, uso de um produto de combinação, e, método para tratar câncer | |
BR112012018951A2 (pt) | composição farmacêutica, combinação farmacêutica e método para o tratamento e\ou prevenção de um câncer e anticorpo | |
BRPI0922475A2 (pt) | composto, composição farmacêutica , método para tratar câncer, e, uso de um composto. | |
BRPI0720546A2 (pt) | Composto, inibidor, medicamento, agente antitumor, composição farmacêutica, método para tratar câncer, e, uso do composto | |
BR112012018947A8 (pt) | composição farmacêutica para o tratamento e/ou prevenção de um câncer, anticorpo, combinação farmacêutica e método para o tratamento e/ou prevenção de um câncer | |
CL2007003226A1 (es) | Compuestos derivados de piridinona; composicion farmaceutica; y uso para tratar el cancer. | |
BRPI0919238A2 (pt) | métodos e composições para o tratamento de câncer | |
ZA200807934B (en) | Cancer treatments | |
BRPI0908635A2 (pt) | composto, composição farmacêutica e método de tratamento de câncer | |
BRPI0909164A2 (pt) | método e composições para o tratamento de câncer | |
BRPI0811059A2 (pt) | combinação, composição farmacêutica, método para tratar câncer em um animal de sangue quente, e, uso de uma combinação | |
BR112013033078A2 (pt) | partícula, composição farmacêutica, conjunto para o tratamento do câncer e método para o tratamento do câncer em um paciente | |
EP2125002A4 (en) | TREATMENT OF SKIN CANCER | |
AP2011005681A0 (en) | Methods and formulations for treating chronic liver disease. | |
BRPI0818323A2 (pt) | composição farmacêutica, uso de uma composição farmacêutica, e, método para tratar câncer. | |
EP2224919A4 (en) | METHOD AND COMPOSITIONS FOR THE TREATMENT OF CANCER, TUMORS AND TUMOR-RELATED DISEASES | |
BRPI1010874A2 (pt) | composição para o tratamento de câncer de próstata | |
BRPI0822012A2 (pt) | Derivados de quinazolina de 6,7-dialcóxi úteis para o tratamento de distúrbios relacionados com câncer | |
BRPI0909016A2 (pt) | anticorpos úteis para o tratamento do câncer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |